"BRCA2 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A large, nuclear protein, encoded by the BRCA2 gene (GENE, BRCA2). Mutations in this gene predispose humans to breast and ovarian cancer. The BRCA2 protein is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev. 2000;14(11):1400-6)
| Descriptor ID |
D024682
|
| MeSH Number(s) |
D12.776.313.249 D12.776.624.776.101 D12.776.660.105
|
| Concept/Terms |
BRCA2 Protein- BRCA2 Protein
- FANCD1 Protein
- Fanconi Anemia Complementation Group D1 Protein
- Fanconi Anemia Group D1 Protein
- BRCA2 Gene Product
- Breast Cancer 2 Gene Product
- Fanconi Anemia Group D1 Complementing Protein
- Breast Cancer 2 Protein
|
Below are MeSH descriptors whose meaning is more general than "BRCA2 Protein".
Below are MeSH descriptors whose meaning is more specific than "BRCA2 Protein".
This graph shows the total number of publications written about "BRCA2 Protein" by people in this website by year, and whether "BRCA2 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 6 | 8 | 14 |
| 2018 | 10 | 1 | 11 |
| 2019 | 3 | 2 | 5 |
| 2020 | 1 | 3 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "BRCA2 Protein" by people in Profiles.
-
Exploring the real-world effect of the SARS-CoV-2 pandemic on the molecular diagnostics for cancer patients and high-risk individuals. Expert Rev Mol Diagn. 2021 01; 21(1):101-107.
-
Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic. Eur J Med Genet. 2020 Dec; 63(12):104098.
-
Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. J Immunother Cancer. 2020 08; 8(2).
-
Breast cancer screening of mutation carriers in the era of COVID-19 pandemic. Int J Cancer. 2020 12 15; 147(12):3574-3575.
-
BRCA testing in a genomic diagnostics referral center during the COVID-19 pandemic. Mol Biol Rep. 2020 Jun; 47(6):4857-4860.
-
RE: BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2020 04 01; 112(4):426-427.
-
Analysis of polymorphisms in genes associated with the FA/BRCA pathway in three patients with multiple primary malignant neoplasms. Artif Cells Nanomed Biotechnol. 2019 Dec; 47(1):1101-1112.
-
Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases. Eur J Surg Oncol. 2019 Nov; 45(11):2096-2102.
-
Alterations in DNA Damage Repair Genes in Primary Liver Cancer. Clin Cancer Res. 2019 08 01; 25(15):4701-4711.
-
Homologous recombination deficiency in triple negative breast cancer. Breast. 2019 Jun; 45:15-21.